Raymond Debbane
Director at Lexicon Pharmaceuticals; Insider at WW International. Based in The Woodlands, Texas.
- Rank
- 7002nd of 14,644
- Companies held
- 2
- Largest holding
- LXRX, 92.1% of total
- Latest SEC filing
- Jun 3, 2026
- Listed but not counted
- $74.0M
What the $13.5M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals LXRX Common Stock | Through Invus US Partners LLC | 5,451,204 | $1.67 | $9.1M | 67.4% | Form 4, Jun 3, 2026 |
| Lexicon Pharmaceuticals LXRX Common Stock | Directly | 1,995,498 | $1.67 | $3.3M | 24.7% | Form 4, Jun 3, 2026 |
| WW International WW Common Stock | Directly | 134,387 | $7.97 | $1.1M | 7.9% | Form 4, May 9, 2023 |
Share counts are the amounts Raymond Debbane reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Raymond Debbane's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals LXRX Common Stock | Through Invus, L.P. and related parties Held by an investment fund or partnership | 35,402,689 | $1.67 | $59.1M | — | Form 4, Jun 3, 2026 |
| Lexicon Pharmaceuticals LXRX Common Stock | Through Invus Public Equities, L.P. and related parties Held by an investment fund or partnership | 7,362,368 | $1.67 | $12.3M | — | Form 4, Jun 3, 2026 |
| Lexicon Pharmaceuticals LXRX Common Stock | Through Avicenna Life Sci Master Fund LP and related parties Held by an investment fund or partnership | 1,538,462 | $1.67 | $2.6M | — | Form 4, Jun 3, 2026 |
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Bought | LXRX | 2,000 | $1.49 | $3K | View |
| Feb 23, 2026 | Bought | LXRX | 100,000 | $1.47 | $147K | View |
| Feb 20, 2026 | Bought | LXRX | 100,000 | $1.48 | $148K | View |
| Feb 19, 2026 | Bought | LXRX | 50,000 | $1.44 | $72K | View |
| Feb 18, 2026 | Bought | LXRX | 133,688 | $1.32 | $176K | View |
| Feb 17, 2026 | Bought | LXRX | 76,857 | $1.31 | $101K | View |
| Feb 13, 2026 | Bought | LXRX | 57,952 | $1.31 | $76K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 6999 | John E. Maupin, Jr., D.D.S Director, Encompass Health. Lakewood Ranch, FL | $13.5M |
| 7000 | John T. Schwieters Director, Danaher. Waltham, MA | $13.5M |
| 7001 | James P. Snee PRESIDENT AND CEO, Hormel Foods. Phoenix, AZ | $13.5M |
| 7002 | Raymond Debbane Director, Lexicon Pharmaceuticals. The Woodlands, TX | $13.5M |
| 7003 | Paul James Lawrence SVP & Chief Financial Officer, Commercial Metals. Irving, TX | $13.5M |
| 7004 | Kenneth A. Jacobson Chief Financial Officer, Avnet. Phoenix, AZ | $13.5M |
| 7005 | Regina L. Gregory See Remarks, Targa Resources. Houston, TX | $13.5M |
Questions
How much stock does Raymond Debbane own?
Raymond Debbane holds $13,507,057 in listed stock based on SEC filings and current prices, mostly Lexicon Pharmaceuticals (LXRX). That ranks 7002nd on the Stock Rich List.
Is this Raymond Debbane's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Raymond Debbane last buy or sell stock?
The most recent open-market trade on file is a purchase of 2,000 LXRX shares on Feb 25, 2026 at $1.49.